169 related articles for article (PubMed ID: 16403626)
1. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
Li Q; Li T; Zhu GD; Gong J; Claibone A; Dalton C; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Bauch JL; Marsh KC; Bouska JJ; Arries S; De Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Mar; 16(6):1679-85. PubMed ID: 16403626
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
[TBL] [Abstract][Full Text] [Related]
3. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
[TBL] [Abstract][Full Text] [Related]
4. Identification of inhibitors of protein kinase B using fragment-based lead discovery.
Saxty G; Woodhead SJ; Berdini V; Davies TG; Verdonk ML; Wyatt PG; Boyle RG; Barford D; Downham R; Garrett MD; Carr RA
J Med Chem; 2007 May; 50(10):2293-6. PubMed ID: 17451234
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
Lin X; Murray JM; Rico AC; Wang MX; Chu DT; Zhou Y; Del Rosario M; Kaufman S; Ma S; Fang E; Crawford K; Jefferson AB
Bioorg Med Chem Lett; 2006 Aug; 16(16):4163-8. PubMed ID: 16765046
[TBL] [Abstract][Full Text] [Related]
6. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants.
Breitenlechner CB; Friebe WG; Brunet E; Werner G; Graul K; Thomas U; Künkele KP; Schäfer W; Gassel M; Bossemeyer D; Huber R; Engh RA; Masjost B
J Med Chem; 2005 Jan; 48(1):163-70. PubMed ID: 15634010
[TBL] [Abstract][Full Text] [Related]
7. Azole-based inhibitors of AKT/PKB for the treatment of cancer.
Zeng Q; Allen JG; Bourbeau MP; Wang X; Yao G; Tadesse S; Rider JT; Yuan CC; Hong FT; Lee MR; Zhang S; Lofgren JA; Freeman DJ; Yang S; Li C; Tominey E; Huang X; Hoffman D; Yamane HK; Fotsch C; Dominguez C; Hungate R; Zhang X
Bioorg Med Chem Lett; 2010 Mar; 20(5):1559-64. PubMed ID: 20137943
[TBL] [Abstract][Full Text] [Related]
8. AKT crystal structure and AKT-specific inhibitors.
Kumar CC; Madison V
Oncogene; 2005 Nov; 24(50):7493-501. PubMed ID: 16288296
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
Woods KW; Fischer JP; Claiborne A; Li T; Thomas SA; Zhu GD; Diebold RB; Liu X; Shi Y; Klinghofer V; Han EK; Guan R; Magnone SR; Johnson EF; Bouska JJ; Olson AM; de Jong R; Oltersdorf T; Luo Y; Rosenberg SH; Giranda VL; Li Q
Bioorg Med Chem; 2006 Oct; 14(20):6832-46. PubMed ID: 16843670
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.
Collins I; Caldwell J; Fonseca T; Donald A; Bavetsias V; Hunter LJ; Garrett MD; Rowlands MG; Aherne GW; Davies TG; Berdini V; Woodhead SJ; Davis D; Seavers LC; Wyatt PG; Workman P; McDonald E
Bioorg Med Chem; 2006 Feb; 14(4):1255-73. PubMed ID: 16249095
[TBL] [Abstract][Full Text] [Related]
11. 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics.
Zeng Q; Bourbeau MP; Wohlhieter GE; Yao G; Monenschein H; Rider JT; Lee MR; Zhang S; Lofgren J; Freeman D; Li C; Tominey E; Huang X; Hoffman D; Yamane H; Tasker AS; Dominguez C; Viswanadhan VN; Hungate R; Zhang X
Bioorg Med Chem Lett; 2010 Mar; 20(5):1652-6. PubMed ID: 20137932
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.
Thomas SA; Li T; Woods KW; Song X; Packard G; Fischer JP; Diebold RB; Liu X; Shi Y; Klinghofer V; Johnson EF; Bouska JJ; Olson A; Guan R; Magnone SR; Marsh K; Luo Y; Rosenberg SH; Giranda VL; Li Q
Bioorg Med Chem Lett; 2006 Jul; 16(14):3740-4. PubMed ID: 16678413
[TBL] [Abstract][Full Text] [Related]
13. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
[TBL] [Abstract][Full Text] [Related]
14. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
Rhodes N; Heerding DA; Duckett DR; Eberwein DJ; Knick VB; Lansing TJ; McConnell RT; Gilmer TM; Zhang SY; Robell K; Kahana JA; Geske RS; Kleymenova EV; Choudhry AE; Lai Z; Leber JD; Minthorn EA; Strum SL; Wood ER; Huang PS; Copeland RA; Kumar R
Cancer Res; 2008 Apr; 68(7):2366-74. PubMed ID: 18381444
[TBL] [Abstract][Full Text] [Related]
15. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
Ashwell MA; Lapierre JM; Brassard C; Bresciano K; Bull C; Cornell-Kennon S; Eathiraj S; France DS; Hall T; Hill J; Kelleher E; Khanapurkar S; Kizer D; Koerner S; Link J; Liu Y; Makhija S; Moussa M; Namdev N; Nguyen K; Nicewonger R; Palma R; Szwaya J; Tandon M; Uppalapati U; Vensel D; Volak LP; Volckova E; Westlund N; Wu H; Yang RY; Chan TC
J Med Chem; 2012 Jun; 55(11):5291-310. PubMed ID: 22533986
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.
Zhu GD; Gong J; Gandhi VB; Woods K; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Stoll VS; Mamo M; Li Q; Rosenberg SH; Giranda VL
Bioorg Med Chem; 2007 Mar; 15(6):2441-52. PubMed ID: 17258463
[TBL] [Abstract][Full Text] [Related]
18. The involvement of phosphatidylinositol 3-kinase in gonadotropin-releasing hormone-induced gonadotropin alpha- and FSHbeta-subunit genes expression in clonal gonadotroph LbetaT2 cells.
Mutiara S; Kanasaki H; Harada T; Oride A; Miyazaki K
Mol Cell Endocrinol; 2008 Feb; 283(1-2):1-11. PubMed ID: 18206295
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure based optimization of novel Akt inhibitors.
Lippa B; Pan G; Corbett M; Li C; Kauffman GS; Pandit J; Robinson S; Wei L; Kozina E; Marr ES; Borzillo G; Knauth E; Barbacci-Tobin EG; Vincent P; Troutman M; Baker D; Rajamohan F; Kakar S; Clark T; Morris J
Bioorg Med Chem Lett; 2008 Jun; 18(11):3359-63. PubMed ID: 18456494
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of peanut serine/threonine/tyrosine protein kinase: molecular docking and inhibition kinetics with tyrosine kinase inhibitors.
Rudrabhatla P; Rajasekharan R
Biochemistry; 2004 Sep; 43(38):12123-32. PubMed ID: 15379551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
